Do drivers with epilepsy have higher rates of motor vehicle accidents than those without epilepsy?

Epilepsy Behav

Department of Neurology, Hofstra NSLIJ School of Medicine, 300 Community Drive, Manhasset, NY 11030, USA. Electronic address:

Published: June 2015

Objective: We sought to understand the magnitude of the risk that drivers with epilepsy (DWE) contribute to motor vehicle accidents (MVAs) compared to other drivers.

Methods: We performed an evidence-based, systematic review using the American Academy of Neurology (AAN) guideline methodology.

Results: Contributory evidence consisted of six Class II studies and one Class III study. Two articles reported a trend toward a decreased rate of overall MVA rates for DWE when compared with the general population with a relative risk (RR) of 0.86 (95% CI: 0.65-1.14) (Class III) and a RR of 1.00 (95% CI: 0.95-1.06) (Class II); both studies used patient report to ascertain MVA rates. Three Class II studies reported either a trend toward or an increased risk of MVA rates for DWE when compared with the general population with a RR of 1.62 (95% confidence interval (CI): 0.95-2.76), as ascertained by insurance, emergency department, and physician reporting databases, a RR of 1.73 (95% CI 1.58-1.90), as ascertained by police reports, and a RR of 7.01 (95% CI 2.18-26.13), as ascertained by casualty department visits. One Class II study showed that, compared to fatal crashes with DWE, fatal crashes were 26 times more likely to occur because of other medical conditions and 156 times more likely to occur because of alcohol abuse. Motor vehicle accident crashes due to seizures in DWE occurred in one out of every 2800 MVAs, as reported in another Class II study.

Conclusions: The evidence for the difference in MVA rates in DWE compared to the general population is inconsistent, and no conclusion can be made. Important methodological differences across the studies contribute to the imprecision. Future research should be performed using objective measures rather than self-reporting of MVAs by DWE and "miles driven" as the denominator to calculate MVA rates.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yebeh.2015.04.016DOI Listing

Publication Analysis

Top Keywords

mva rates
20
motor vehicle
12
class studies
12
rates dwe
12
dwe compared
12
compared general
12
general population
12
drivers epilepsy
8
vehicle accidents
8
class iii
8

Similar Publications

Background/objectives: Marburg virus (MARV) is the etiological agent of Marburg Virus Disease (MVD), a rare but severe hemorrhagic fever disease with high case fatality rates in humans. Smaller outbreaks have frequently been reported in countries in Africa over the last few years, and confirmed human cases outside Africa are, so far, exclusively imported by returning travelers. Over the previous years, MARV has also spread to non-endemic African countries, demonstrating its potential to cause epidemics.

View Article and Find Full Text PDF

Introduction: To investigate the maternal and fetal outcomes of pregnant patients who were involved in a motor vehicle accident (MVA).

Materials And Methods: This retrospective, single-center study was conducted at a tertiary care center. A total of 66 patients who experienced an MVA between November 2019 and February 2024 were included.

View Article and Find Full Text PDF

Purpose: Autistic adults experience high rates of traumatic events and PTSD. However, little work has evaluated motor vehicle accident (MVA) related trauma symptoms. The goal of this brief report was to provide pilot data characterizing MVA-related peritraumatic reactions, trauma symptoms, and rates of PTSD diagnosis and mental health service use among Autistic compared to non-autistic adults.

View Article and Find Full Text PDF

Background: Biomarker testing in metastatic non-small lung cancer (NSCLC) is critical for appropriate treatment. Claims-based datasets offer real-world information on the use and cost of biomarker testing.

Materials And Methods: We used 2013-2021 data from Optum's de-identified Clinformatics Data Mart Database.

View Article and Find Full Text PDF

Treatment of metastatic breast cancer by stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS).

Discov Oncol

December 2024

Division of Breast Surgery, Department of General Surgery, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, 610041, China.

Background And Purpose: The role of local ablative radiotherapy (stereotactic body radiotherapy (SBRT)/stereotactic radiosurgery (SRS)) in the management of metastatic breast cancer (mBC) patients remains unclear. This study aimed to assess the efficacy of SBRT/SRS in oligometastatic and oligoprogressive breast cancer patients.

Methods: Totally 80 mBC patients with oligometastatic disease (OMD) and 80 with oligoprogressive disease (OPD) to ≤5 metastatic lesions were retrospectively analyzed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!